Schistosomiasis is a chronic parasitic disease, caused by Schistosoma spp, afflicting more than 200 million people globally. Schistosoma haematobium is the causative agent of urinary schistosomiasis and the most common disease form in Africa.
Significant differences in infectivity and disease severity among individuals exposed to same rates of infection have been observed in endemic communities. Also, host genetics seems to be a mitigating factor in determining who gets infected. Six single nucleotide polymorphisms of the suppression of tumorigenicity 2 (ST2) gene have been found to show differing relationship with Schistosoma japonicum and Schistosoma mansoni. Surprisingly there is no information on Schistosoma haematobium. How these polymorphisms mediate infectivity and disease severity between West and East Africa is yet to be delineated. This study will decipher the genetic diversity of ST2 genetic polymorphisms (rs127112135; rs1041973; rs10173081; rs1420101; rs6543119 and rs10206753) between disease and control groups, quantify soluble ST2 levels and evaluate expression of ST2 gene in S. haematobium infected and uninfected control groups, recruited from south-western, Nigeria.
Genomic DNA will be extracted using a commercially available DNA extraction kit. ST2 SNPs will be genotyped by PCR followed by restriction digestion. ST2 Serum levels will be measured using commercially available enzyme-linked immunosorbent assay. Total RNA will be extracted using commercially available kit. RNA concentration and purity will be assessed with a NanoDrop, and reverse transcribed to cDNA using a commercially available 2 step Reverse transcriptase kit. cDNA Quantitative PCR will be performed using specific primers and probes on TaqMan Real time PCR platform.